SNUS Sonus Pharmaceuticals (MM)

Sonus Pharmaceuticals, Inc. (NASDAQ:SNUS) will release third quarter financial results on Wednesday, November 8, after the close of market. At 4:30 P.M. ET, management will host a conference call to provide a company update. The conference call will be web cast live at 1:30 P.M. PT/4:30 P.M. ET on November 8 and can be accessed at www.sonuspharma.com/events.html. A web cast replay of the call will be available through the same link. A telephone replay will also be available from November 8, 4:30 P.M. PT/7:30 P.M. ET, for one week at 800-379-7444 or 303-590-3000 for international calls; Pass code 11074216. About Sonus Pharmaceuticals Located near Seattle, Washington, Sonus Pharmaceuticals is focused on the development of drugs that provide better therapeutic alternatives for cancer patients, including improved efficacy, safety and tolerability, and are more convenient to use. The Company�s lead oncology product candidate, TOCOSOL� Paclitaxel, is currently in a Phase 3 pivotal trial for the potential treatment of metastatic breast cancer. TOCOSOL Paclitaxel is a ready-to-use, injectable formulation of the widely prescribed anti-cancer drug, paclitaxel. Formulated with Sonus� proprietary vitamin-E based TOCOSOL technology, TOCOSOL Paclitaxel may have the ability to reduce treatment-limiting side effects and improve anti-tumor activity. Submission of the New Drug Application for TOCOSOL Paclitaxel is expected by the end of 2007. In October 2005, Sonus entered into a licensing agreement with Schering AG for the development and commercialization of TOCOSOL Paclitaxel. The Company moved its second product candidate, TOCOSOL Camptothecin, into Phase 1 clinical development in September 2006. TOCOSOL Camptothecin is a new entry in the same drug class as the approved camptothecin analogs, irinotecan and topotecan. Preclinical data suggest that TOCOSOL Camptothecin may be more efficacious and better tolerated than irinotecan. For additional information on Sonus, including news releases, please visit www.sonuspharma.com. Safe Harbor Certain statements made in this press release are forward-looking such as those, among others, relating to the development, safety and efficacy of therapeutic drugs and potential applications for these products. As discussed in Sonus Pharmaceuticals� filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for 2005 and Quarterly Report on Form 10-Q for the second quarter of 2006, actual results could differ materially from those projected in the forward-looking statements as a result of the following factors, among others: the Company�s products will require extensive clinical testing and approval by regulatory authorities; such approvals are lengthy and expensive and may never occur; risks that the Company will not be able to complete the Phase 3 clinical trial for TOCOSOL Paclitaxel; risks that clinical studies with TOCOSOL Paclitaxel will not be successful; risks that the FDA may not approve the TOCOSOL Paclitaxel New Drug Application; risks that the Phase 1 clinical trial for TOCOSOL Camptothecin will not be successful; risks of successful development of therapeutic drugs; and risks that the Company may not be successful in obtaining funding from third parties or completing a financing necessary to support the costs and expenses of clinical studies as well as research and development activities. The Company undertakes no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof. Sonus Pharmaceuticals, Inc. (NASDAQ:SNUS) will release third quarter financial results on Wednesday, November 8, after the close of market. At 4:30 P.M. ET, management will host a conference call to provide a company update. The conference call will be web cast live at 1:30 P.M. PT/4:30 P.M. ET on November 8 and can be accessed at www.sonuspharma.com/events.html. A web cast replay of the call will be available through the same link. A telephone replay will also be available from November 8, 4:30 P.M. PT/7:30 P.M. ET, for one week at 800-379-7444 or 303-590-3000 for international calls; Pass code 11074216. About Sonus Pharmaceuticals Located near Seattle, Washington, Sonus Pharmaceuticals is focused on the development of drugs that provide better therapeutic alternatives for cancer patients, including improved efficacy, safety and tolerability, and are more convenient to use. The Company's lead oncology product candidate, TOCOSOL(R) Paclitaxel, is currently in a Phase 3 pivotal trial for the potential treatment of metastatic breast cancer. TOCOSOL Paclitaxel is a ready-to-use, injectable formulation of the widely prescribed anti-cancer drug, paclitaxel. Formulated with Sonus' proprietary vitamin-E based TOCOSOL technology, TOCOSOL Paclitaxel may have the ability to reduce treatment-limiting side effects and improve anti-tumor activity. Submission of the New Drug Application for TOCOSOL Paclitaxel is expected by the end of 2007. In October 2005, Sonus entered into a licensing agreement with Schering AG for the development and commercialization of TOCOSOL Paclitaxel. The Company moved its second product candidate, TOCOSOL Camptothecin, into Phase 1 clinical development in September 2006. TOCOSOL Camptothecin is a new entry in the same drug class as the approved camptothecin analogs, irinotecan and topotecan. Preclinical data suggest that TOCOSOL Camptothecin may be more efficacious and better tolerated than irinotecan. For additional information on Sonus, including news releases, please visit www.sonuspharma.com. Safe Harbor Certain statements made in this press release are forward-looking such as those, among others, relating to the development, safety and efficacy of therapeutic drugs and potential applications for these products. As discussed in Sonus Pharmaceuticals' filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for 2005 and Quarterly Report on Form 10-Q for the second quarter of 2006, actual results could differ materially from those projected in the forward-looking statements as a result of the following factors, among others: the Company's products will require extensive clinical testing and approval by regulatory authorities; such approvals are lengthy and expensive and may never occur; risks that the Company will not be able to complete the Phase 3 clinical trial for TOCOSOL Paclitaxel; risks that clinical studies with TOCOSOL Paclitaxel will not be successful; risks that the FDA may not approve the TOCOSOL Paclitaxel New Drug Application; risks that the Phase 1 clinical trial for TOCOSOL Camptothecin will not be successful; risks of successful development of therapeutic drugs; and risks that the Company may not be successful in obtaining funding from third parties or completing a financing necessary to support the costs and expenses of clinical studies as well as research and development activities. The Company undertakes no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof.